EntreMed’s Thalidomide Analog in Phase I Multiple Myeloma Trial
ROCKVILLE, Maryland-En-treMed, Inc. has begun a phase I study of its thalidomide derivative ENMD 0995 at the Mayo Clinic, Rochester, Minnesota, in patients with multiple myeloma. ENMD 0995 recently received orphan drug designation from the FDA for the disease.
ROCKVILLE, MarylandEn-treMed, Inc. has begun a phase I study of its thalidomide derivative ENMD 0995 at the Mayo Clinic, Rochester, Minnesota, in patients with multiple myeloma. ENMD 0995 recently received orphan drug designation from the FDA for the disease.
The agent is a small molecular analog of thalidomide with improved angiogenesis inhibitor activity that, in animal models, does not show evidence of the toxic side effects reported for thalidomide, the company said in a news release.
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
